FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 330:436-438 February 10, 1994 Number 6 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Nightingale, S. D.

To the Editor: The article on rifabutin prophylaxis against Mycobacterium avium complex disease by Nightingale et al. (Sept. 16 issue)¹ provides important information. We are perplexed by one point, however. How, in a randomized trial of 1146 patients, could the group treated with rifabutin have a 14 percent higher mean base-line CD4+ lymphocyte count, the key surrogate marker of the progression of human immunodeficiency virus (HIV) disease (mean CD4+ count, 63.5 cells per cubic millimeter, as compared with 55.5 cells per cubic millimeter for patients in the placebo group)? On the basis of data given in Table 1 of the . . . [Full Text of this Article]

References

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.